Skip to content

Investor Relations / SEC Filings

SEC Filings

Filing date Form Filer Description View
4 THERO JOHN F

Statement of changes in beneficial ownership of securities

View HTML
4 KENNEDY JOSEPH T

Statement of changes in beneficial ownership of securities

View HTML
4 Ketchum Steven B

Statement of changes in beneficial ownership of securities

View HTML
4 Kalb Michael Wayne

Statement of changes in beneficial ownership of securities

View HTML
4 Berg Aaron

Statement of changes in beneficial ownership of securities

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4 THERO JOHN F

Statement of changes in beneficial ownership of securities

View HTML

Data provided by Kaleidoscope.

copyright
© 2021, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
Spaces South Docklands
Block C
77 Sir John Rogerson's Quay
Dublin 2, D02 VK60
Investor Relations
AMARIN CORPORATION PLC C/O AMARIN PHARMA, INC.
440 ROUTE 22
BRIDGEWATER, NJ 08807
investor.relations@amarincorp.com
Fax:
+1 908 719 3012

Amarin Corporation